Imperial Innovations reports strong progress in top three portfolio companies

Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results.

Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results.

The firm said that in the six months ended January 31st its top three portfolio companies, namely Circassia, Nexeon and Veryan Medical, which represent 52.8% of the value of the portfolio, had all moved closer to commercialisation.

However, this success has yet to feed through into revenues, which remained stable at £1.61m, or pre-tax profits, which dipped from £0.93m to £0.92m.

That said, the company is very confident about its outlook and said it expects to see either the sale of one of its portfolio companies or the sale of one of its products within the next 12 months.

The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have confirmed that a single successful phase III trial of Circassia's cat allergy product will be sufficient to begin sales, while Veryan Medical has achieved CE mark approval, clearing the way for product launch in Europe.

Nexeon will complete its new manufacturing plant in July and have product available for sale this year.

The group said that it was continuing to focus on its plan to "grow good businesses that have a good syndicate of backers behind them" and is looking to set all of its companies in a position of stength.

In the second half of the year the company anticipates a similar level of investment of £14m.

The group explained that it looks to recognise and realise the value added to its companies at appropriate points, saying it believes that this value creation "will be reflected in higher portfolio valuations in due course".

Chairman of the group Martin Knight said: "Our portfolio companies are developing well, building long-term value as they progress towards commercialisation.

"Our other significant investee companies, including PolyTherics, PsiOxus Therapeutics, Oxford Immunotec, Cortexica and Cell Medica, have also made substantial commercial and technical progress.

"The portfolio has a satisfactory depth and spread of technological activity, which the directors believe bodes well for a sustained and sizeable increase in the valuation of our investments."

The share price was unchanged.

NR

Recommended

Get healthy returns from these three healthcare stocks
Share tips

Get healthy returns from these three healthcare stocks

Professional investor Paul Major of the BB Healthcare Trust highlights three of his favourite healthcare stocks.
25 Oct 2021
Share tips of the week – 22 October
Share tips

Share tips of the week – 22 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Oct 2021
Three dividend stocks from the dynamic Asia/Pacific region
Share tips

Three dividend stocks from the dynamic Asia/Pacific region

Professional investor Sat Duhra of the Henderson Far East Income investment trust highlights three of his favourite stocks.
18 Oct 2021
Share tips of the week – 15 October
Share tips

Share tips of the week – 15 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
15 Oct 2021

Most Popular

Properties for sale for around £1m
Houses for sale

Properties for sale for around £1m

From a stone-built farmhouse in the Snowdonia National Park, to a Victorian terraced house close to London’s Regent’s Canal, eight of the best propert…
15 Oct 2021
How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
Emerging markets: the Brics never lived up to their promise – but is now the time to buy?
Emerging markets

Emerging markets: the Brics never lived up to their promise – but is now the time to buy?

Twenty years ago hopes were high for Brazil, Russia, India and China – the “Brics” emerging-market economies. But only China has beaten expectations. …
18 Oct 2021